Comparative efficacy and safety of targeted therapeutics or immunotherapy agents combined with chemotherapy as first-line treatment for advanced biliary tract cancer: a systematic review and network meta-analysis.

Furthermore, two targeted drugs (Cetuximab and Infigratinib) showed nearly statistically significant improvements in terms of ORR (OR 2.19, 95% CI 0.88–5.43) in mutation-targeted therapy subgroup.

also in 323 other papers

Meanwhile, Durvalumab had a statistically significant difference in prolonging the OS compared to Cetuximab (HR 0.71, 95% CI 0.51–0.98) and Pembrolizumab showed a trend toward prolonging the OS compared to Cetuximab (HR 0.77, 95% CI 0.57–1.05).

also in 53,322 other papers